Luminex Plc · CSELK:LUMX.N0000
Luminex — 33rd Annual J.P. Morgan Healthcare Conference 2015
19 slides from Luminex's conference presentation, Jan 12, 2015
Slide 1: 33rd Annual J.P. Morgan Healthcare Conference
N AC H U M “ H O MI ” S H A MI R P R E S I D E N T A N D C H I E F E X E C U T I V E O F F I C E R 3 3 R D A N N UA L J . P. M O R G A N H E A LT H C A R E C O N F E R E N C E J A N U A R Y 1 5 , 2 0 1 5
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT 2 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Certa in statements made dur ing the course o f th is presentat io n may not be purely h istor ica l and conseque nt l y may be forward lo o k ing statements w ith in the mea
Slide 3: Who We Are
WHO WE ARE 3 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science A Foundation Built on Multiplexing - From only one sample, detect and identify up to 500 biological agents - Improves time, cost, and productivity - Distributed by Key Industry Player
Slide 4: Partnership Channel Funding Growth in Molecular Channel
PARTNERSHIP CHANNEL FUNDING GROWTH IN MOLECULAR CHANNEL 4 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Stable, Strong & Profitable Partnership Channel - Annualized 2014 Revenue: ~$118M [1] - CAGR [2] - Royalties: 15% - Consumables: 6% - Syst
Slide 5: Growing Emphasis on Diagnostics
Diagnostics – Direct 38% Diagnostics – Partner 35% Research – Partner 27% GROWING EMPHASIS ON DIAGNOSTICS 5 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science YTD 2014 Revenue [1] Research – Partner 40% Diagnostics – Direct 23% Diagnostics – Partner
Slide 6: Positioning for Accelerating Growth in Molecular Diagnostics
Positioning for Accelerating Growth in Molecular Diagnostics With Launches of ARIES and NxTAG 2015 – YEAR OF TRANSITION 6 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science ATTRACTIVE Markets Leadership position in growing multibillion dollar market
Slide 7: The Established Leader in Multiplex Testing
THE ESTABLISHED LEADER IN MULTIPLEX TESTING 7 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Detect and identify up to 500 biological agents • Save time • Decrease cost • Increase productivity 11,200+ Instruments placed 700+ Assays Developed 65
Slide 8: ARIES: Solution-Based Product Innovation
ARIES®: SOLUTION-BASED PRODUCT INNOVATION 8 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science • Contamination and Misdiagnosis • Varying Testing Platforms • Limited Bench Space • Scarcity of Highly Trained Personnel • High Volume of Reports Challen
Slide 9: ARIES Timeline to Commercial Launch
Complete Development ARIES® TIMELINE TO COMMERCIAL LAUNCH Clinical Trials Start 2H14 1Q15E Summer 15E FDA 510(k) Submission/ RUO Launch 4Q15E Target Date for FDA Clearance All 5+ Assays Cleared 2Q16E 9 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance scie
Slide 10: ARIES Initial Launch Menu Market Opportunity
Launch Offering Market Opportunity ARIES® INITIAL LAUNCH MENU 10 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Source: Market Diagnostics International (MDxI); Kalorama 2013 Report on Molecular Diagnostics and internal estimates $1B+ Initial Me
Slide 11: NxTAG RPP: Streamlines Workflow Without Sacrificing Throughput
NXTAG® RPP: STREAMLINES WORKFLOW WITHOUT SACRIFICING THROUGHPUT 11 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Hands-on Time: 20-25 min Time to Results: < 4 hrs • Comprehensive Multiplex Panel • Minimal Hands-on Time • Rapid Turnaround Time •
Slide 12: NxTAG RPP Timeline
RUO Launch NXTAG® RPP TIMELINE Clinical Trials Start 1Q15E 2Q15E Summer 15E FDA 510(k) Submission 4Q15E Target Date for FDA Clearance 12 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science
Slide 13: Expanding Downstream with ARIES
A R I E S Full MDx (500) Moderately Complex MDx (1000) Limited MDx (5,000) No MDx Capability (7,000) EXPANDING DOWNSTREAM WITH ARIES Source: Mdxi Market Diagnostics Int’l, Emmes Database (2013): 1,000 U.S. laboratory survey, Scientia Analysis, AHA Registered U.S. Hospitals, CMS CLIA 13 | © Copyright
Slide 14: Consistent Top-Line Growth
50 100 150 200 250 2010 2011 2012 2013 2014E Total Revenue ($M) CONSISTENT TOP-LINE GROWTH [1] 4-year CAGR based on Mid-point of 2014 guidance range over 2010 [2] 2014 revenue guidance as of 3Q14 earnings call, October 27, 2014 14 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to im
Slide 15: Strong Gross and Operating Margins
[1] Non-GAAP Operating margin for years 2010-2014 exclude litigation fees, restructuring, severance, and settlement of distributor agreements [2] YTD 2014 figures as of September 30, 2014 STRONG GROSS AND OPERATING MARGINS 15 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve
Slide 16: My Day One Initial Observations
MY 90 DAY INITIAL OBSERVATIONS 16 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science Focus On Execution Partnership Challenge Next Generation Sequencing Operational Improvements Announced on 3Q14 earnings call: “We expect consumable revenue to be
Slide 17: Key Takeaways: How We Win
KEY TAKEAWAYS: HOW WE WIN 17 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science • Utilize Brand Recognition and Reputation While Expanding Addressable Market • Offer a Complete Testing Solution • Focus on Execution, Organizational Synergy and Becomi
Slide 18: Thank You
Luminex. THANK YOU
Slide 19: Appendix: Non-GAAP Reconciliation
[1] Non-GAAP Operating margin for years 2010-2014 exclude litigation fees, restructuring, severance, and settlement of distributor agreements [2] YTD 2014 figures as of September 30, 2014 APPENDIX: NON-GAAP RECONCILIATION 19 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve
Luminex — 33rd Annual J.P. Morgan Healthcare Conference 2015 on 6ix